These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 26352769)

  • 21. ROS1 [corrected].
    Pal P; Khan Z
    J Clin Pathol; 2017 Dec; 70(12):1001-1009. PubMed ID: 28903995
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Personalized medicine in non-small-cell carcinoma].
    Iwama E; Takayama K; Baba E; Nakanishi Y
    Fukuoka Igaku Zasshi; 2014 Mar; 105(3):57-66. PubMed ID: 25000657
    [No Abstract]   [Full Text] [Related]  

  • 23. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
    Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
    J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Crizotinib for ROS1 patients: One small step in biomarker testing, one giant leap for advanced NSCLC patients.
    Juan O; Popat S
    Lung Cancer; 2017 Feb; 104():131-133. PubMed ID: 27863911
    [No Abstract]   [Full Text] [Related]  

  • 25. ROS1-targeted therapy in non-small cell lung cancer.
    Sequist LV
    Clin Adv Hematol Oncol; 2012 Dec; 10(12):827-8. PubMed ID: 23271356
    [No Abstract]   [Full Text] [Related]  

  • 26. [Treatment of advanced non-small-cell lung cancer with driver mutations].
    Tessmer A; Kollmeier J
    Dtsch Med Wochenschr; 2015 Mar; 140(5):323-8. PubMed ID: 25734673
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.
    Davare MA; Vellore NA; Wagner JP; Eide CA; Goodman JR; Drilon A; Deininger MW; O'Hare T; Druker BJ
    Proc Natl Acad Sci U S A; 2015 Sep; 112(39):E5381-90. PubMed ID: 26372962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Crizotinib in the management of advanced-stage non-small-cell lung cancer.
    Loong HH; Mok K; Leung LK; Mok TS
    Future Oncol; 2015; 11(5):735-45. PubMed ID: 25757678
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation.
    Lee JK; Kim TM; Koh Y; Lee SH; Kim DW; Jeon YK; Chung DH; Yang SC; Kim YT; Kim YW; Heo DS; Bang YJ
    Lung Cancer; 2012 Aug; 77(2):460-3. PubMed ID: 22622260
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.
    Song A; Kim TM; Kim DW; Kim S; Keam B; Lee SH; Heo DS
    Clin Cancer Res; 2015 May; 21(10):2379-87. PubMed ID: 25688157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Personalized therapy for lung cancer: striking a moving target.
    Pakkala S; Ramalingam SS
    JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual potent ALK and ROS1 inhibitors combating drug-resistant mutants: Synthesis and biological evaluation of aminopyridine-containing diarylaminopyrimidine derivatives.
    Guo M; Zuo D; Zhang J; Xing L; Gou W; Jiang F; Jiang N; Zhang D; Zhai X
    Eur J Med Chem; 2018 Oct; 158():322-333. PubMed ID: 30223120
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bronchoscopic Re-biopsy for Mutational Analysis of Non-small Cell Lung Cancer.
    Kirita K; Izumo T; Matsumoto Y; Hiraishi Y; Tsuchida T
    Lung; 2016 Jun; 194(3):371-8. PubMed ID: 26951235
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development.
    Wijesinghe P; Bollig-Fischer A
    Adv Exp Med Biol; 2016; 890():1-23. PubMed ID: 26703796
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ROS1 as a 'druggable' receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway.
    Ou SH; Tan J; Yen Y; Soo RA
    Expert Rev Anticancer Ther; 2012 Apr; 12(4):447-56. PubMed ID: 22500682
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis.
    Ahn HK; Han B; Lee SJ; Lim T; Sun JM; Ahn JS; Ahn MJ; Park K
    Lung Cancer; 2012 May; 76(2):253-4. PubMed ID: 22385925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer.
    Kaczmar J; Mehra R
    Ther Adv Respir Dis; 2015 Oct; 9(5):236-41. PubMed ID: 26229087
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New and emerging targeted treatments in advanced non-small-cell lung cancer.
    Hirsch FR; Suda K; Wiens J; Bunn PA
    Lancet; 2016 Sep; 388(10048):1012-24. PubMed ID: 27598681
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ROS1-rearranged Non-small Cell Lung Cancer.
    Giustini NP; Bazhenova L
    Thorac Surg Clin; 2020 May; 30(2):147-156. PubMed ID: 32327173
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting FGFR, ephrins, Mer, MET, and PDGFR-α in non-small cell lung cancer.
    Riess JW; Neal JW
    J Thorac Oncol; 2011 Nov; 6(11 Suppl 4):S1797-8. PubMed ID: 22005534
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.